Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Matinas BioPharma Holdings, Inc. (MTNB) Starts Presentation at LD Micro Conference

Posted on December 3, 2015 by MissionIR

Matinas BioPharma Holdings, Inc. (OTC: MTNB) is a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective antifungal and anti-bacterial therapeutics for the treatment of serious and life-threatening infections. The company’s lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. For more information, visit the company’s website at www.matinasbiopharma.com.

The three-day LD Micro Invitational in Bel Air, California, features company presentations from more than 200 select high-potential small-cap companies spanning multiple industries. Institutional and retail investors in attendance also have access to numerous networking opportunities and social events to learn more about these companies. For more information on LD Micro, visit www.ldmicro.com
This entry was posted in LD Micro Conference. Bookmark the permalink.

Comments are closed.